• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Brian Orelli

Articles by Brian Orelli

Blockchain building out in the drug industry

Feb. 26, 2018
By Brian Orelli
Blockchain, the transaction-following technology that got its fame as a way to follow the movements of cryptocurrencies such as Bitcoin, is making its way into the pharmaceutical industry, proving its potential uses are far-flung.
Read More

Blockchain building out in the drug industry

Feb. 26, 2018
By Brian Orelli
Blockchain, the transaction-following technology that got its fame as a way to follow the movements of cryptocurrencies such as Bitcoin, is making its way into the pharmaceutical industry, proving its potential uses are far-flung.
Read More

Sleeper data: Early stage efficacy, plus plenty of genes to explore

Feb. 12, 2018
By Brian Orelli
Despite being the second most prevalent mental disorder with a third of the general population reporting insomnia complaints and 10 percent meeting the strict definition of insomnia disorder, the treatment options for the disease are lacking. Considering that many treatments lead to tolerance and dependence and the potential for morning sedation, drugs using new mechanisms of action are sorely needed.
Read More

Looking to boost sales, drugs tackle liver cancer

Jan. 29, 2018
By Brian Orelli
After a drought of nearly a decade without an FDA approval, the market for hepatocellular carcinoma (HCC), the most common type of primary liver cancer in adults, is heating up.
Read More

Companies look to help cancer patients by preventing side effect

Jan. 16, 2018
By Brian Orelli
Oral mucositis, painful sores that form in the mouths of many cancer patients, are more than just an annoying side effect of radiation and chemotherapy treatments. When they reach grade 3, patients can no longer eat solid foods, and at grade 4 patients can no longer even drink, often resulting in the stopping of cancer treatments.
Read More

Regeneron, Sanofi throw more money into partnership (x 2)

Jan. 9, 2018
By Brian Orelli
In what seems to be an eternally growing partnership, Regeneron Pharmaceuticals Inc. and Sanofi SA plan to accelerate development of two drugs already partnered under their multidrug agreements.
Read More

Roche Ignyta fire in M&A targeted therapy takeout

Dec. 27, 2017
By Brian Orelli

Roche 'Ignyta' fire in M&A targeted therapy takeout

Dec. 27, 2017
By Brian Orelli
Roche Holding AG is acquiring San Diego-based Ignyta Inc. for $1.7 billion with an offer of $27 per share in cash, a 74 percent increase over its closing price on Thursday.
Read More

Aerie gets present from the FDA in Rhopressa early nod

Dec. 20, 2017
By Brian Orelli
Christmas came early for Aerie Pharmaceuticals Inc. with an FDA approval of Rhopressa (netarsudil) for open-angle glaucoma or ocular hypertension on Monday – or maybe call it an early Valentine's Day gift considering the PDUFA goal date wasn't until Feb. 28, 2018.
Read More

Companies seek HIV holy grails: A vaccine or a cure

Dec. 11, 2017
By Brian Orelli
Many companies have tried and failed to make an HIV vaccine capable of preventing HIV infection, but the virus has eluded more than 30 vaccines so far.
Read More
Previous 1 2 … 18 19 20 21 22 23 24 25 26 … 55 56 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 27, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 27, 2025.
  • Vertex divulges new Nav1.8 blockers for pain

    BioWorld Science
    Vertex Pharmaceuticals Inc. has synthesized sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • DNA NGS genome sequencing

    GC Genome plans $30M IPO to diversify genomic products, suppliers

    BioWorld
    GC Genome Corp. priced a Kosdaq offering of 4 million shares at ₩10,500 per share May 27, entailing a gross ₩42 billion (US$30.5 million) raise in early June. The...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe